Hypothetically, if those Vaxinia patients who achieved reduced tumour burden or stable disease started to see further improvement as their immune system slowly recovered, then, strategically, would you cut, cleanse and publish that data, or would you want to back that up in parallel with some data from Oasis and Oncarlytics. If the outcome is licensing or takeover, that initial cut of Oasis and Oncarlytics data is far more valuable, in my opinion, and worth waiting on and presenting together.
If there was no confidence in the data to date (and in my opinion, there wasn't), then why continue with trials at all, including dose escalating.
This is life and death for real people participating in the trials, so it is totally idiotic and reprehensible for some to suggest those patients' lives are being used to fund a lifestyle company.
The above is just my musings, maybe wishful thinking. But unfortunately, updates take time. Some have even written scientific papers on it.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6145729/
IMU Price at posting:
3.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)